Analgesic Injection Franchise in Ahmedabad

Decplist Max Injection Supplier in Mumbai

Pain Relief Injection Distributor in Delhi

Diclofenac + Paracetamol Injection Manufacturer in Bangalore

Anti-Inflammatory Injection Stockist in Hyderabad
Analgesic Injection Exporter in Chandigarh

Home/Products /diclofenac-50mg-paracetamol-500-mg-tablet

Decplist Max Injection

Composition : Diclofenac (75mg) + Paracetamol (225mg) Injection

Dosage Form : Injection

Packaging Type : Ampule

Packaging : 10x1ml

Price : ₹0/-

Decplist Max Injection contains Diclofenac 75 mg and Paracetamol 225 mg, a combination analgesic and anti-inflammatory therapy designed for rapid relief of acute pain and inflammation. Diclofenac inhibits prostaglandin synthesis to reduce inflammation and swelling, while Paracetamol provides central analgesic action for effective pain control.

Clinically, this combination is indicated for postoperative pain, musculoskeletal pain, joint disorders, and acute inflammatory conditions. The synergistic action ensures faster pain relief and improved patient comfort compared to monotherapy.

The injection formulation ensures precise dosing, rapid onset of action, and consistent therapeutic outcomes, making it suitable for hospitals, surgical centers, emergency care units, and specialty clinics. Intravenous or intramuscular administration allows immediate pain control in acute scenarios.

Decplist Max Injection contributes to enhanced recovery, reduced inflammation, and improved patient mobility, making it a trusted choice for acute pain management. Its evidence-based combination ensures safety and efficacy under strict medical supervision.

Read More

About the Product

Decplist Max Injection contains Diclofenac 75 mg and Paracetamol 225 mg, a combination analgesic and anti-inflammatory therapy designed for rapid relief of acute pain and inflammation. Diclofenac inhibits prostaglandin synthesis to reduce inflammation and swelling, while Paracetamol provides central analgesic action for effective pain control.

Clinically, this combination is indicated for postoperative pain, musculoskeletal pain, joint disorders, and acute inflammatory conditions. The synergistic action ensures faster pain relief and improved patient comfort compared to monotherapy.

The injection formulation ensures precise dosing, rapid onset of action, and consistent therapeutic outcomes, making it suitable for hospitals, surgical centers, emergency care units, and specialty clinics. Intravenous or intramuscular administration allows immediate pain control in acute scenarios.

Decplist Max Injection contributes to enhanced recovery, reduced inflammation, and improved patient mobility, making it a trusted choice for acute pain management. Its evidence-based combination ensures safety and efficacy under strict medical supervision.

Common side effects may include nausea, vomiting, mild gastrointestinal discomfort, headache, and dizziness. Rare but serious effects include gastrointestinal bleeding, renal impairment, hypersensitivity reactions, and liver enzyme abnormalities.

Decplist Max Injection is indicated for the management of acute musculoskeletal pain, post-operative pain, joint pain, and other painful inflammatory conditions, as prescribed by a healthcare professional.

Use Decplist Max Injection strictly under medical supervision. Caution is advised in patients with a history of gastrointestinal disorders, liver or kidney impairment, cardiovascular disease, or NSAID hypersensitivity. Monitor for signs of allergic reactions, gastrointestinal bleeding, or abnormal liver function.

Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children. Use the prepared injection immediately or as per guidelines.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation